Chris Raymond
Chris Raymond
bit blunt patients physicians struggle
I think you're going to see a bit of a struggle between patients and physicians going forward, which I think can blunt the near-term uptake of the drug.
hitting issue stock stride trade
I don't think they have an issue in the marketplace. Operationally, they're hitting their stride ... but this is a stock that has to trade on more near-term earnings.